Association of CTLA-4 gene polymorphisms with sporadic breast cancer risk and clinical features in Han women of Northeast China

Molecular and Cellular Biochemistry

Volumn 364, Issue 1-2, 2012, Pages 283-290

  Li, Dalin ^a   Zhang, Qiujin ^a   Xu, Fengyan ^a   Fu, Zhenkun ^a   Yuan, Weiguang ^a   Li, Dianjun ^a   Pang, Da ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Cytotoxic T lymphocyte antigen 4; Haplotype; Polymorphism

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ESTROGEN RECEPTOR; GENOMIC DNA; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL FEATURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 GENE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; BREAST NEOPLASMS; CHINA; CTLA-4 ANTIGEN; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HAPLOTYPES; HUMANS; LYMPH NODES; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RISK; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863984515     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-012-1228-8     Document Type: Article

References (35)

1. Coughlin SS, Ekwueme DU (2009) Breast cancer as a global health concern. Cancer Epidemiol 33(5):315-318
2. Welch DR, Steeg PS, Rinker-Schaeffer CW (2000) Molecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis. Breast Cancer Res 2(6):408-416 (Pubitemid 32223637)
3. Reeves GK, Travis RC, Green J, Bull D, Tipper S, Baker K, Beral V, Peto R, Bell J, Zelenika D, Lathrop M (2010) Incidence of breast cancer and its subtypes in relation to individual and multiple low-penetrance genetic susceptibility loci. JAMA 304(4):426-434
4. DeNardo DG, Coussens LM (2007) Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 9(4):212
5. Whiteside TL (2010) Immune responses to malignancies. J Allergy Clin Immunol 125:S272-S283
6. Ghaderi A, Yeganeh F, Kalantari T, Talei AR, Pezeshki AM, Doroudchi M, Dehaghani AS (2004) Cytotoxic T lymphocyte antigen-4 gene in breast cancer. Breast Cancer Res Treat 86(1):1-7 (Pubitemid 38918893)
7. Fu Z, Li D, Jiang W, Wang L, Zhang J, Xu F, Pang D, Li D (2010) Association of BTLA gene polymorphisms with the risk of malignant breast cancer in Chinese women of Heilongjiang Province. Breast Cancer Res Treat 120(1):195-202
8. Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter A, Anasetti C, Damle NK (1992) Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 176:1595-1604
9. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green GM, Thompson CB, Bluestone JA (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405-413
10. van der Merwe P, Bodian D, Daenke S, Linsley PS, Davis SJ (1997) CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 185:393-403 (Pubitemid 27078358)
11. Appleman LJ, Berezovskaya A, Grass I, Boussiotis VA (2000) CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J Immunol 164:144-151 (Pubitemid 30012984)
12. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S (2008) CTLA-4 control over Foxp3 + regulatory T cell function. Science 322:271-275
13. O'Day SJ, Hamid O, Urba WJ (2007) Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 110:2614-2627 (Pubitemid 350250330)
14. Menard C, Ghiringhelli F, Roux S, Chaput N, Mateus C, Grohmann U, Caillat-Zucman S, Zitvogel L (2008) Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res 14:5242-5249
15. Erfani N, Razmkhah M, Talei AR, Pezeshki AM, Doroudchi M, Monabati A, Ghaderi A (2006) Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer. Cancer Genet Cytogenet 165:114-120 (Pubitemid 43343504)
16. Wang L, Li D, Fu Z, Li H, Jiang W, Li D (2007) Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population. BMC cancer 7:173
17. Hudson LL, Rocca K, Song YW, Pandev JP (2002) CTLA-4 gene polymorphisms in systemic lupus erythematosus: a highly significant association with a determinant in the promoter region. Hum Genet 111:452-455 (Pubitemid 36075075)
18. Ban Y, Concepcion ES, Villanueva R, Greenberg DA, Davies TF, Tomer Y (2004) Analysis of immune regulatory genes in familial and sporadic Graves' disease. J Clin Endocrinol Metab 89(9):4562-4568 (Pubitemid 39244470)
19. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263-265 (Pubitemid 40202029)
20. Loizidou MA, Michael T, Neuhausen SL, Newbold RF, Marcou Y, Kakouri E, Daniel M, Papadopoulos P, Malas S, Kyriacou K, Hadjisawas A (2008) Genetic polymorphisms in the DNA repair genes XRCC1, XRCC2, and XRCC3 and risk of breast cancer in Cyprus. Breast Cancer Res Treat 112(3):575-579
21. Hurwitz AA, Kwon ED, van Elsas A (2000) Costimulatory wars: the tumor menace. Curr Opin Immunol 12:589-596
22. Chen L (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4:336-347 (Pubitemid 38649276)
23. Wang XB, Pirskanen R, Giscombe R, Lefvert AK (2008) Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis. J Intern Med 263:61-69 (Pubitemid 350243551)
24. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ (2000) CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 165:6606-6611
25. Hughes TA (2006) Regulation of gene expression by alternative untranslated regions. Trends Genet 22:119-122 (Pubitemid 43290014)
26. Ueda H, Howson JM, Esposito L et al (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506-511 (Pubitemid 36648570)
27. Anjos SM, Shao W, Marchand L, Polychronakos C (2005) Allelic effects on gene regulation at the autoimmunity-predisposing CTLA4 locus: a re-evaluation of the 3' +6230G>A polymorphism. Genes Immun 6:305-311 (Pubitemid 40903403)
28. Mayans S, Lackovic K, Nyholm C, Lindgren P, Ruikka K, Eliasson M, Cilio CM, Holmberg D (2007) CT60 genotype does not affect CTLA-4 isoform expression despite association to T1D and AITD in northern Sweden. BMC Med Genet 8:3
29. Beenken SW, Grizzle WE, Crowe DR, Conner MG, Weiss HL, Sellers MT, Krontiras H, Urist MM, Bland KI (2001) Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53. Ann Surg 233:630-638 (Pubitemid 32378646)
30. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW (2008) An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 107:309-330 (Pubitemid 351172108)
31. Ponzone R, Biglia N, Jacomuzzi ME, Mariani L, Dominguez A, Sismondi P (2006) Antihormones in prevention and treatment of breast cancer. Ann N Y Acad Sci 1089:143-158 (Pubitemid 47092092)
32. Group EBCTC (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
33. Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Nicholson RI, Lee AH, Robertson JF, Rllis IO (2007) Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 25:4772-4778 (Pubitemid 350086480)
34. Hernández J, Ko A, Sherman LA (2001) CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen. J Immunol 166:3908-3914 (Pubitemid 32224917)
35. Espenschied J, Lamont J, Lonqmate J, Pendas S, Wang Z, Diamond DJ, Ellenhorn JD (2003) CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol 170:3401-3407 (Pubitemid 36302220)